Intelligent human diagnostic and therapy platform

Projektinformationen

Cardiacom IMPLANT

ID Finanzhilfevereinbarung: 663197

DOI 10.3030/663197

Abgeschlossenes Projekt

EK-Unterschriftsdatum 13 Februar 2015

Startdatum 1 Dezember 2014

Enddatum 28 Februar 2015

Finanziert unter

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

ATRACTOR KUTATASI, FEJLESZTESI ES SZOLGALTATO KFT
Hungary

Ziel

In OECD countries the most frequent cause of mortality is cardiovascular diseases. Addressing this problem needs a holistic approach, where ICT-based monitoring is in the focus.

The disruptive innovation programme sets the target of performing complex mobile invasive monitoring of cardiovascular and associated diseases, of forecasting the state of the patients, supporting the therapy treatments and assessing the effectiveness of drugs on mobile information-technology-base.

The devices are miniature holter monitors built into the human body, which with their diagnostic algorithm will regularly or continuously assess and check the physiological condition of the users.

Innovation content: 7/24 monitoring, continous data processing, intelligent automated evaluation systems, lifelong mobile crisis management, optimized drug taking protocol, implants with long life.

Main ecomic benefits: higher health and life safety, higher economic efficiency as a result of the improvement in people health condition, less patient-doctor appointment, reduced cost of cardiovascular treatment, reduced number of operations.

Main target group: patients who have been/will be operated on any cardiovascular disease and people who have high risk factor.
The business model is built on the sale of appliances and on the sale of the related subscription-based info-communication service packages. According to the initial financial plan we count with a turnover of 100.000 pieces and an outstanding profit and return by the end of the fifth year after the market launch.

We plan the diffusion of the system in three steps with expanding geographical coverage. Before entering the markets we establish dealerships in the regions and develop a regional distributor and technical support system as well.

As desired achievements of the phase 1 five main parts of the Feasibility Study will be elaborated: Market Analysis Business Plan, Marketing Plan, Legal and Organisational Plan and Technological Plan.

Wissenschaftliches Gebiet

• medical and health sciences › health sciences › health care services › eHealth
• social sciences › sociology › demography › mortality
• social sciences › economics and business › business and management › business models
• medical and health sciences › clinical medicine › cardiology › cardiovascular diseases
• social sciences › sociology › governance › crisis management

Programm/Programme

• H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) Main Programme
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

Thema/Themen

• ICT-37-2014-1 - Open Disruptive Innovation Scheme (implemented through the SME instrument)

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2014

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

ATRACTOR KUTATASI, FEJLESZTESI ES SZOLGALTATO KFT

• Netto-EU-Beitrag: € 50 000,00
• Adresse: HERMINA UT. 57-59 ; 1146 BUDAPEST ; Ungarn
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Közép-Magyarország › Budapest › Budapest
• Region: Közép-Magyarország › Budapest › Budapest
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00